Visual summary only. The research findings, limitations and references accompany the card on this page.
Calf-thymus-derived polypeptide preparation No fixed constituent count, mixture ratio, formula or molecular mass is asserted. Biological settings and research diagrams are illustrations, not measured anatomy or clinical outcomes.
Thymalin
Multiple cellular immune readouts
Thymalin: calf-thymus-derived polypeptide preparation/mixture- Identity
- Calf-thymus peptide preparation
- Composition
- Mixture; not a single sequence
- Boundary
- Not thymosin α1
Research snapshot
Thymalin is a thymus-derived peptide preparation, not one sequence-defined molecule. Experimental work examines immune-cell differentiation and inflammatory readouts; mixture composition and preparation-specific evidence must remain explicit.
In-vitro human-cell experiments
Identity & representation
Literature reference substance only; no equivalence to a catalog product or tested supplier lot is asserted. A preparation containing multiple peptides. Reported constituent dipeptides include Glu-Trp and Lys-Glu; these are not an exhaustive composition or a fixed mixture ratio. Not thymosin alpha1.
Educational reference only. Not a dosing guide, treatment recommendation or product endorsement.
Sources checked: 2026-11-06. Identity and evidence limits are stated above. Independent specialist review is pending.
What researchers study
Thymalin is a thymus-derived peptide preparation, not one sequence-defined molecule. Experimental work examines immune-cell differentiation and inflammatory readouts; mixture composition and preparation-specific evidence must remain explicit.
Human hematopoietic-cell differentiation markers
Cytokine output in stimulated peripheral immune cells
Identification of constituent thymic peptides
Mechanism / evidence map
- Thymus-derived peptide mixture
- Cell differentiation or cytokines measured
- Mechanistic interpretation remains provisional
No single molecular target or atomistic structure represents the mixture. Component docking hypotheses are not established whole-preparation mechanisms.
Simplified publication-grounded schematic, not a solved protein structure or proof of clinical benefit.
Selected evidence
Clinical reports exist, but the selected mechanistic papers are laboratory experiments; they do not establish general clinical efficacy or longevity benefit.
Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.[2]
In-vitro human-cell experiment · Human hematopoietic stem-cell cultures · Culture experiment
Observed: Thymalin changed markers associated with hematopoietic stem-cell and T-cell differentiation.
Limit: Cell marker changes do not establish infection prevention, immune rejuvenation or clinical benefit.
The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.[3]
In-vitro donor-cell assays plus computational analysis · Peripheral blood mononuclear cells from 4 donors · Experimental assay windows · Reported n: 4
Observed: Thymalin and studied EW/KE dipeptides reduced IL-1β, IL-6 andTNF-α production in LPS-stimulated peripheral blood mononuclear cells.
Limit: Four donors; molecular docking and inferred gene targets are hypotheses; not a clinical COVID-19 trial.
Reference identity in detail
Sequences and form distinctions describe the cited reference substance, not a verified supplier preparation.
Safety & evidence limits
Thymalin is a mixture; no single sequence, formula or molecular mass can honestly represent the entire preparation.
Results from isolated EW or KE dipeptides cannot be treated as results for an identical whole-extract product.
Cell and computational findings do not establish human immune rejuvenation, infection prevention or lifespan extension.
Practical identity notes
- Calf-thymus peptide preparation; composition is not one defined molecule.
- EW and KE are reported constituents, not a complete ingredient list or fixed ratio.
- No molecular formula, mass, exact atom graph or3D conformer assigned.
- Mixture; preparation-specific evidence • Reference form only
The 10-second takeaway
A thymus-peptide mixture with preparation-specific laboratory findings, not a single molecule or established human longevity intervention.
What the visual panels show
Original diagrams summarize the cited research or documented evidence search. They are not copied publication figures or claims of treatment benefit.
EVIDENCE / IDENTITY CONTEXT[1][2][3]
Publication-grounded mechanism schematic · Original publication-grounded diagram
Thymus-derived peptide mixture · Differentiation and cytokines measured · Mechanistic interpretation remains provisional
Interpretation: No single molecular target or atomistic structure represents the mixture. Component docking hypotheses are not established whole-preparation mechanisms.
Preparation, not molecule[1][3]
MIXTURE IDENTITY · Original publication-grounded diagram
Multiple peptides; EW / KE components reported
No unique molecular graph or single target represents the mixture.
Interpretation: No unique molecular graph or single target represents the mixture. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.
Differentiation-marker changes[2]
HUMAN-CELL CULTURE · Original publication-grounded diagram
Stem-cell / T-cell-associated markers changed
Human-derived cells are not a human clinical trial.
Interpretation: Human-derived cells are not a human clinical trial. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.
LPS-stimulated cytokines[3]
FOUR-DONOR CELL ASSAYS · Original publication-grounded diagram
IL-1β, IL-6 and TNF-α production decreased
PBMC assays; docking hypotheses do not establish clinical benefit.
Interpretation: PBMC assays; docking hypotheses do not establish clinical benefit. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.
Follow the evidence
Sources & what they support
- Natural and synthetic thymic peptides as therapeutics for immune dysfunction.
Supports: Calf-thymus extraction, mixture versus isolated dipeptide distinction
- Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.
Supports: Human-cell differentiation experiment
- The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.
Supports: Four-donor cytokine assays; computational hypotheses
- Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats.
Supports: EW is an isolated synthetic constituent; rat findings are not whole-Thymalin evidence
← Explore the Molecular Atlas Continue to the research library →
